AM
Therapeutic Areas
Protagonist Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Icotrokinra (JNJ-2113) | Moderate-to-Severe Plaque Psoriasis | Approved |
| Rusfertide (PTG-300) | Polycythemia Vera | Phase 3 |
| Oral Hepcidin Program | Polycythemia Vera, Hereditary Hemochromatosis | Preclinical |
| PN-881 | Psoriasis, PsA, Hidradenitis Suppurativa, Spondyloarthritis | Phase 1 |
| PN-477 (SC) | Obesity & Co-morbidities | IND-Enabling |
| PN-477 (Oral) | Obesity & Co-morbidities | IND-Enabling |